Military Medical Academy J. E. Purkyně, Hradec Králové, Czechoslovakia; Department of Clinical Oncology, Faculty of Medicine, Hradec Králové, Czechoslovakia
This study was designed, to evaluate the effect of Coparvax (Corynebacterium parvum, Wellcome) on growth of L1210 leukemic cells in ascites of DBA/2 mice. 100 viable tumour cells were inoculated intraperitoneally in the mice. Coparvax (50 mg/kg) administered 7 days before tumour cells significantly decreases the number of tumour cells in the peritoneal cavity (7th and 11th day after application of tumour cells). Coparvax administered recurrently (once a week, the first administration was provided 7 days before application of leukemic cells) decreases the number of tumour cells 11th day after application of cells as well in comparison with the group, where Coparvax was administered unrepeatedly.
Mean time of mice ruvival after application of leukemic cells determinated at 11.5 days in untreated mice was prolonged to 15 days after administration of Coparvax. We observed that administration of Coparvax to normal mice resulted in an increase of the spleen weight, the number of leucocytes in blood and the number of cells in peritoneal cavity.
Suppressive efect of Coparvax on growth of L1210 leukemic cells in acsites
